Amendment No. 1 to the RESEARCH Collaboration AgreementResearch Collaboration Agreement • May 12th, 2022 • Nkarta, Inc. • Pharmaceutical preparations
This Amendment No. 1 to the Research Collaboration Agreement (the “Amendment”) is entered into as of May 4, 2022 (“Amendment Effective Date”) by and between Nkarta, Inc. (“Nkarta”) and CRISPR Therapeutics AG (“CRISPR”). Nkarta and CRISPR each may be referred to herein individually as a “Party” or collectively as the “Parties.” This Amendment amends the Research Collaboration Agreement, entered into as of May 5, 2021, between Nkarta and CRISPR, as supplemented (the “Agreement”). Capitalized terms used but not defined in this Amendment shall have the meanings ascribed to such terms in the Agreement.
